Sign up to save your podcasts
Or
Share Why we should look at continuing CD38 antibodies after progression
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Why we should look at continuing CD38 antibodies after progression
There is an explosion of trials in the CD38 antibody space (daratumumab, isatuximab) in multiple myeloma. This episode goes over one key unanswered question which many of the trials are not attempting to answer.
View all episodes
By Ming-Hei TaiThere is an explosion of trials in the CD38 antibody space (daratumumab, isatuximab) in multiple myeloma. This episode goes over one key unanswered question which many of the trials are not attempting to answer.